SCHEMBL3278529

SCHEMBL3278529

O=C(NCC(=O)N1CCN(CCCN2CCCC2)CC1)c1ccc(S(=O)(=O)N(Oc2ccccc2)c2ccccc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.44
CA12 O43570 2/20 0.42
CA9 Q16790 2/20 0.42
SIGMAR1 Q99720 1/20 0.42
RAB9A P51151 3/20 0.41
GAA P10253 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
KMT2A Q03164 2/20 0.40
USP5 P45974 1/20 0.39
MEN1 O00255 1/20 0.39
NAMPT P43490 1/20 0.39
ALDH1A1 P00352 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
USP2 O75604 1/20 0.39
MAPK1 P28482 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
P2RY12 Q9H244 1/20 0.39
THRA P10827 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3274986 0.96 NPC1 (0.46) NPC1CA12CA9SIGMAR1RAB9A
SCHEMBL15103768 0.91 NPC1 (0.53) NPC1RAB9AGAASMN1; SMN2KMT2A
SCHEMBL3277926 0.91 SMN1; SMN2 (0.43) NPC1CA12CA9SIGMAR1RAB9A
SCHEMBL15103734 0.90 NPC1 (0.52) NPC1RAB9AGAASMN1; SMN2KMT2A
SCHEMBL15103782 0.90 NPC1 (0.52) NPC1RAB9AGAASMN1; SMN2KMT2A
SCHEMBL15103797 0.90 NPC1 (0.52) NPC1RAB9AGAASMN1; SMN2KMT2A
SCHEMBL15103911 0.90 P2RX7 (0.46) NPC1CA12CA9SIGMAR1RAB9A
SCHEMBL15103840 0.89 NAMPT (0.42) NPC1SIGMAR1RAB9AGAASMN1; SMN2
SCHEMBL3273954 0.89 SMN1; SMN2 (0.44) NPC1CA12CA9SIGMAR1RAB9A
SCHEMBL15103961 0.88 CXCR3 (0.45) NPC1CA12CA9RAB9AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2076491-B1 NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT (HU) 2013-07-17 EP claimed
US-8481527-B2 Benzamide derivatives as bradykinin antagonists RICHTER GEDEON NYRT. (HU) 2013-07-09 US claimed
US-20100087423-A1 NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2010-04-08 US claimed
EP-2076491-B1 NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT (HU) 2013-07-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087423-A1 NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS BDKRB1, BDKRB2, HRH1 NPC1 2456/4885CA12 4157/4885CA9 3245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.